HLC 001
Alternative Names: HLC-001Latest Information Update: 28 Sep 2023
At a glance
- Originator Human Life CORD Japan
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Lung disorders
- No development reported SARS-CoV-2 acute respiratory disease
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for phase-I development in SARS-COV-2 acute respiratory disease in Japan (IV, Infusion)
- 14 Dec 2022 Phase-II clinical trials in Lung disorders (Treatment-resistant) (Parenteral) prior to December 2022
- 30 Sep 2022 Human Life CORD Japan completes a phase-I clinical trials in SARS-COV-2 acute respiratory disease in Japan (IV) (Japic CTI-205465)